POEM (Patient-Oriented Eczema Measure)
- Introduced by
- Charman CR, Venn AJ, Williams HC
- Year
- 2004
- Type
- Self-report
- Family
- patient-reported-severity
What does it do?
The POEM is a brief, patient-administered severity measure for atopic dermatitis that focuses on frequency of symptoms experienced over the past week.
Developed by Charman, Venn, and Williams in 2004, it emphasizes the patient's lived experience rather than clinician observation, making it practical for routine clinical practice and remote monitoring. POEM is increasingly used alongside objective measures in clinical trials and outpatient care.
The intuition behind the method
Clinician-rated measures like SCORAD and EASI provide detailed objective assessment but require appointments and clinician expertise. POEM captures what matters most to patients: frequency of itching, sleep loss, and visible signs (dryness, cracking, oozing). By asking 'How many days this week did you have X?', POEM is simple, quick, and responsive to changes in daily symptom burden. This makes it valuable for longitudinal tracking and for populations (infants, telemedicine) where clinician examination is impractical.
History
POEM was developed and published in 2004 by Charman and colleagues at the University of Nottingham as a response to the need for a patient-centered, practical severity measure. It was derived from qualitative research exploring what symptoms mattered most to patients with atopic dermatitis. Since its publication, POEM has been translated into 20+ languages, validated in both pediatric and adult populations, and increasingly adopted in clinical trials as a secondary or co-primary endpoint. The WHO Quality of Life team has endorsed POEM as a patient-reported outcome measure. It is particularly popular in European and UK dermatology settings and is increasingly used in Asia-Pacific regions.
When to use it
POEM is ideal for longitudinal monitoring in both clinical practice and trials, particularly when frequent assessment is needed (weekly or bi-weekly). It is especially useful for telemedicine visits, home-based monitoring, and populations unable to attend in-person clinician assessments. POEM complements objective measures; in modern trials, POEM and an objective measure (EASI or SCORAD) are often used together. For pure severity grading at a single timepoint, a clinician-rated measure may be preferred, but POEM is superior for tracking change and capturing patient experience.
Limitations and considerations
- Subjective recall; patients may not accurately remember symptom frequency over a 7-day period, especially for mild symptoms.
- Does not capture clinician-observable signs (extent, lichenification, induration); purely symptom-based.
- Ceiling effects possible in very severe disease; differentiation between 'every day' responses is limited.
- Culturally sensitive interpretation of terms (e.g., 'oozing') may vary; translations require validation.
- Sleep loss item may conflate atopic dermatitis with other sleep disruptions (stress, comorbid sleep disorders).
- Not suitable for very young children (<2 years); parental proxy rating may underestimate infant symptoms.
Source conditions do not replace independent scientific review or validation by an analysis engine.
Strengths
- Patient-administered; no clinician expertise or training required, enabling use in any setting (primary care, telemedicine, home).
- Practical and brief; completion takes 2–3 minutes; low respondent burden increases compliance.
- Validated from age 2 years upward; reliable in both children and adults.
- Responsive to treatment change; sensitive to clinically meaningful improvement.
- Captures patient-centered outcomes; frequency of itching and sleep loss align with quality-of-life impact.
- Suitable for frequent assessment; symptom frequency over past 7 days enables weekly tracking.
- Strong internal consistency and test-retest reliability in diverse populations.
Applications
- Routine clinical monitoring: Baseline and periodic (every 2–4 weeks) self-assessment during topical or systemic therapy to track symptom burden and guide treatment decisions.
- Telemedicine assessment: Remote follow-up visits where clinician examination is not feasible; POEM is suitable for phone or video consultations.
- Clinical trial secondary endpoint: Patient-reported outcome measure in combination with objective measures (EASI, SCORAD) to provide multidimensional efficacy assessment.
- Home-based monitoring: Patients with chronic or recurrent disease can complete POEM weekly or bi-weekly to identify triggers and optimize maintenance therapy.
- Quality-of-life research: Epidemiological studies and burden-of-disease assessments in which symptom frequency is more relevant than clinician-observed signs.
How it works
How it works
The patient (or parent/caregiver for children <4 years) completes the seven-item POEM questionnaire, typically during a routine visit or at home. Each item asks about symptom frequency during the past 7 days: 'How many days have you/has your child had [symptom]?' Response options are ordinal: 0 (not at all or one day), 1 (two or three days), 2 (four or five days), 3 (six days), or 4 (every day). Items cover: itching, dryness, cracking, flaking, bleeding/oozing, crusting, and sleep loss. Completion takes 2–3 minutes and requires no clinician input.
Formula
Patient completes self-administered 7-item questionnaire. Each item (days with itching, days with dryness, days with cracking, days with flaking, days with oozing/bleeding, days with oozing/crusting, sleep disruption) is rated on a 0–4 frequency scale (never=0, 1–2 days=1, 3–4 days=2, 5–6 days=3, every day=4) based on symptoms during the past week.
POEM scoring is straightforward: sum the seven item responses (each 0–4) for a total range of 0–28. There are no subscales, weighting, or adjustments. Higher scores indicate greater severity.
Formula
Sum all seven item scores (each 0–4). Total POEM = 0–28. No weighting or subscales.
Severity classification: POEM 0–2 indicates clear or nearly clear skin; 3–7 indicates mild disease; 8–16 indicates moderate disease; 17–24 indicates severe disease; 25–28 indicates very severe disease. A change of ≥3 points from baseline is considered a clinically meaningful improvement. POEM is also validated from infancy (age 2 years) to adulthood, and the same cutoffs apply across ages.
Formula
Severity: 0–2 = clear; 3–7 = mild; 8–16 = moderate; 17–24 = severe; 25–28 = very severe. Change of ≥3 points indicates meaningful improvement. POEM is suitable for age 2 years and above.
Common pitfalls
- Using POEM as the sole severity measure in clinical trials; objective assessment (EASI or SCORAD) should always accompany POEM to capture clinician-observable disease extent and sign intensity.
- Interpreting POEM scores in isolation without understanding the underlying symptoms; a POEM of 8 (mild-moderate) with predominant itching is clinically different from a POEM of 8 with predominant oozing.
- Assuming POEM is interchangeable with SCORAD or EASI; POEM measures symptom frequency, not sign intensity or body surface area involvement, and does not directly correlate with objective measures.
- Failing to assess adherence or understanding; patients may misinterpret 'days' (calendar days vs. nights vs. any symptom during the day).
- Using POEM in infants under 2 years with parental proxy rating without validating the parent's understanding of each symptom.
Frequently asked questions
How is POEM different from SCORAD or EASI?
POEM is patient-reported and captures symptom frequency (itching, sleep loss, visible signs as the patient perceives them) over the past week. SCORAD and EASI are clinician-assessed and measure objective extent and sign intensity at the time of examination. POEM reflects the patient's subjective burden and is useful for tracking change at home. SCORAD and EASI are better for precise severity grading at baseline and for trial outcomes requiring blinded clinician assessment.
Can POEM be used instead of EASI or SCORAD?
POEM should complement, not replace, objective measures in clinical trials. Modern trial designs use both: POEM (patient-reported) and EASI (clinician-assessed) as co-primary efficacy endpoints. In routine practice, POEM alone is adequate for home monitoring and telemedicine; however, baseline assessment should include an objective measure to document disease severity at the start of treatment.
What is the MCID (minimal clinically important difference) for POEM?
The MCID for POEM is approximately 3 points; a reduction of ≥3 points from baseline is considered clinically meaningful improvement. Additionally, a 50% reduction in POEM score (POEM-50 response) is used in some trials as a secondary efficacy endpoint.
Can parents/caregivers accurately report POEM for young children?
Yes, POEM is validated for children aged 2–16 years using parental proxy completion. However, parents' perception of symptoms (particularly itching severity and sleep disruption) may differ from direct observation. For children aged 6+, direct child self-report is encouraged when feasible. For infants under 2 years, POEM is not validated; objective measures are preferred.
How should POEM be adapted for assessment intervals?
POEM asks about symptoms during the past 7 days. For frequent assessments (weekly), this is straightforward. For less frequent monitoring (monthly), the recall period may be extended, but this should be clearly documented and reported. Always state the recall period when reporting POEM scores to enable comparison across studies.
Related methods
Sources
Charman CR, Venn AJ, Williams HC. The Patient-Oriented Eczema Measure: development and initial validation of a new tool for measuring atopic eczema severity from the patients' perspective. Arch Dermatol. 2004;140(12):1513-1519.
Open DOI referenceCopied.Charman CR, Venn AJ, Williams HC. Measurement of body surface area involvement in atopic eczema: an updated comparison of estimation methods. Br J Dermatol. 2005;152(2):288-294.
Open publication referenceCopied.